Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Buy
55
ARAY Quote, Financials, Valuation and Earnings
Last price:
$1.84
Seasonality move
:
7.9%
Day range:
$1.90 - $1.99
52-week range:
$1.40 - $3.03
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.44x
P/B ratio:
4.40x
Volume:
239.1K
Avg. volume:
623.4K
1-year change:
-33.33%
Market cap:
$199.1M
Revenue:
$446.6M
EPS (TTM):
-$0.17
Analysts' Opinion
-
Consensus RatingAccuray has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Accuray has an estimated upside of 209.34% from its current price of $1.98.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $1.98.
Fair Value
-
According to the consensus of 0 analysts, Accuray has 209.34% upside to fair value with a price target of -- per share.
ARAY vs. S&P 500
-
Over the past 5 trading days, Accuray has overperformed the S&P 500 by 8.66% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Accuray does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Accuray revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Accuray reported revenues of $101.5M.
Earnings Growth
-
Accuray earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Accuray reported earnings per share of -$0.04.
Enterprise value:
310.1M
EV / Invested capital:
1.44x
Price / LTM sales:
0.44x
EV / EBIT:
--
EV / Revenue:
0.70x
PEG ratio (5yr expected):
-0.08x
EV / Free cash flow:
-21.79x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
84.67x
Gross Profit (TTM):
$137.9M
Return On Assets:
-3.51%
Net Income Margin (TTM):
-3.72%
Return On Equity:
-35.94%
Return On Invested Capital:
-7.54%
Operating Margin:
-2.12%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $419M | $455M | $444.2M | $103.9M | $101.5M | |
| Gross Profit | $155M | $158.9M | $137.9M | $39.5M | $34.5M | |
| Operating Income | $3.6M | $6.8M | -$3.9M | $2.2M | -$2.1M | |
| EBITDA | $7.1M | $13.2M | $3.7M | $3.1M | $1.1M | |
| Diluted EPS | -$0.11 | -$0.07 | -$0.17 | -$0.03 | -$0.04 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $332.5M | $350.5M | $335.3M | $334.1M | $329.5M | |
| Total Assets | $464.7M | $475.8M | $466.3M | $476.8M | $473.1M | |
| Current Liabilities | $169.1M | $188.3M | $192.5M | $201.4M | $201.8M | |
| Total Liabilities | $397.3M | $430M | $419.4M | $425.9M | $427.9M | |
| Total Equity | $67.4M | $45.8M | $47M | $50.9M | $45.2M | |
| Total Debt | $179.7M | $197.8M | $176.3M | $176M | $170.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $6.2M | $6.9M | -$10.6M | -$8.6M | -$7.3M | |
| Cash From Investing | -$4.5M | -$12.5M | -$3.6M | -$1.1M | -$1.1M | |
| Cash From Financing | -$18.7M | $753K | -$4.6M | -$1.5M | -$2.2M | |
| Free Cash Flow | $1.7M | -$5.6M | -$14.2M | -$9.7M | -$8.4M | |
ARAY
Sector
Market Cap
$199.1M
$46.5M
Price % of 52-Week High
65.35%
47.23%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-33.33%
-31.38%
Beta (5-Year)
1.441
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$1.88
200-day SMA
Buy
Level
$1.94
Bollinger Bands (100)
Buy
Level
1.7 - 2.12
Chaikin Money Flow
Buy
Level
42.1M
20-day SMA
Sell
Level
$1.98
Relative Strength Index (RSI14)
Buy
Level
53.09
ADX Line
Buy
Level
25.65
Williams %R
Neutral
Level
-37.8378
50-day SMA
Buy
Level
$1.91
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
16.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.009)
Sell
CA Score
(Annual)
Level (-1.9143)
Buy
Beneish M-Score
(Annual)
Level (-2.2664)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.9594)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Stock Forecast FAQ
In the current month, ARAY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ARAY average analyst price target in the past 3 months is --.
-
Where Will Accuray Stock Be In 1 Year?
According to analysts, the consensus estimate is that Accuray share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Accuray?
Analysts are divided on their view about Accuray share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Accuray is a Sell and believe this share price will drop from its current level to --.
-
What Is Accuray's Price Target?
The price target for Accuray over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ARAY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Accuray is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ARAY?
You can purchase shares of Accuray via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Accuray shares.
-
What Is The Accuray Share Price Today?
Accuray was last trading at $1.84 per share. This represents the most recent stock quote for Accuray. Yesterday, Accuray closed at $1.98 per share.
-
How To Buy Accuray Stock Online?
In order to purchase Accuray stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is down 3.22% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 4.72% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is down 4.82% over the past day.
